Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC By Ogkologos - January 30, 2026 474 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASCENT-04/KEYNOTE-D19 study Source RELATED ARTICLESMORE FROM AUTHOR Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... MOST POPULAR Stopping the spread: A revolution in how we think about metastasis October 18, 2022 Airbrushed Magazines Hurt the Body Image of Young Women — Here’s... May 19, 2021 Breast Cancer Survivor is Swimming the English Channel to Benefit Mental... July 5, 2021 Targeted Treatment for Rare Digestive Tract Cancers May Extend Survival December 7, 2018 Load more HOT NEWS Study Advances Fertility Preservation Approach for Male Cancer Survivors Study Aims to Reduce Lung Cancer Stigma by Teaching Health Professionals... Does Too Much Fructose Help Colorectal Cancers Grow? 6 of the biggest good news cancer stories of 2021
